Investor Presentation - First Six Months of 2021

6 Investor presentation First six months of 2021 Novo NordiskⓇ Diabetes value market leadership has increased by 0.5%-points to 29.6% Novo Nordisk global diabetes value market share Diabetes value market leadership expansion driven by the GLP-1 franchise 60% 50% 46.6% Diabetes GLP-1 -Insulin 49.1% 51.5% 44.2% 44.6% 43.9% 40% 28.3% 29.1% 29.6% • 30% 0% 2018 2019 2020 2021 CER: Constant exchange rates; IO: International Operations; NAO: North America Operations Source: IQVIA MAT, May 2021 (Spot rate) Note: Sales growth rates are at CER Diabetes care sales grew by 11% with global value market share increase driven by GLP-1 market share gains in both IO and NAO Insulin volume market share has increased from 47.0% to 47.3% in the last 12 months GLP-1 value market share has increased by 2.4%-points in the last 12 months, driven by: OzempicⓇ launched in 62 countries RybelsusⓇ uptake in North America Operations and launches in International Operations

View entire presentation